Insider Transaction Report for Agios Pharmaceuticals, Inc.

Rahul Ballal, a director at Agios Pharmaceuticals, Inc., reported several transactions on June 18, 2026. These include the acquisition of 2,816 shares of common stock, the grant of 2,927 restricted stock units, and the grant of 14,950 stock options. Additionally, 2,816 restricted stock units were disposed of. The stock options have an exercise price of $34.16 and vest on June 18, 2027. The restricted stock units granted on June 18, 2026, also vest on June 18, 2027, with vested shares delivered post-vesting. The transaction involving the acquisition of 2,816 shares of common stock resulted in a post-transaction holding of 15,230 shares.